By Ransdell Pierson 4 minutes ago NEW YORK (Reuters) - Pfizer Inc (PFE.N) on Wednesday said quarterly earnings more than doubled on higher sales of its prescription drugs and lower expenses, but its Chantix quit-smoking drug lost more than a third of its U.S. sales amid safety concerns.The company earned $2.78 billion, or 41 cents per share, in the second quarter. That compared with $1.27 billion, or 18 cents per share, a year earlier, when Pfizer took large charges for restructuring and merger-related costs.
Excluding special items, Pfizer earned 55 cents per share. Analysts on average expected 54 cents per share, according to Reuters Estimates.
Read More